RHYTHM PHARMACEUTICALS, INC.RYTMEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| PRIMECAP Management Company | 11.81% | 7.2M | ▼ -1.82pp | 2024-11-12 |
| Baker Bros. Advisors LP | 10.80% | 6.4M | — | 2024-02-14 |
| BlackRock, Inc. | 10.70% | 6.4M | ▼ -0.30pp | 2024-01-24 |
| Nos. of above persons | 9.95% | 6.1M | ▲ +0.95pp | 2024-11-14 |
| Perceptive Advisors LLC | 8.60% | 5.4M | ▲ +0.30pp | 2024-11-14 |
| THE GOLDMAN SACHS GROUP, INC. | 6.40% | 3.9M | ▼ -2.10pp | 2024-11-12 |
| The Vanguard Group | 5.46% | 3.2M | — | 2024-02-13 |
| STATE STREET CORPORATION | 3.73% | 76.2K | — | 2024-01-23 |
Insider Transactions
Net 90d: −$2.72M · buys $0 / sells $2.72MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-01 | Yann Mazabraud | EVP, Head of International | Option exercise | 12.9K | — | — |
| 2026-03-12 | Mathers Edward T | Director | Other | 4.2K | $0.00 | $0 |
| 2026-03-04 | German Christopher Paul | Corporate Controller & CAO | Option exercise | 1.5K | $17.97 | $27.0K |
| 2026-03-04 | German Christopher Paul | Corporate Controller & CAO | Sell (open market) | 5.6K | $89.56 | $502.8K |
| 2026-03-02 | Mathers Edward T | Director | Other | 4.2K | $0.00 | $0 |
| 2026-03-02 | Smith Hunter C | Chief Financial Officer | Option exercise | 6.1K | $6.80 | $41.5K |
| 2026-03-01 | German Christopher Paul | Corporate Controller & CAO | Option exercise | 1.2K | — | — |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Sell (open market) | 1.3K | $100.27 | $131.2K |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Sell (open market) | 1.7K | $100.92 | $170.8K |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Sell (open market) | 800 | $102.10 | $81.7K |
1–10 of 39
Page 1 / 4